Abstract 929TiP
Background
Studies on patients with cancer and COVID-19 have indicated a high mortality rate compared with the general population. Patients with head and neck cancer are thought to be prone to complications following COVID-19 infection due to their older age, smoking habits, and pre-existing cardiopulmonary comorbidities, in addition to cancer therapy. Our aim is to study the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with head and neck cancers.
Trial design
Head and Neck ancers international COVID-19 Collaboration (HERODOTUS) registry is a multicentre observational study composed of a cross-sectional component and a longitudinal cohort component. Eligibility criteria were the presence of any head and neck cancer and a COVID-19 diagnosis, either laboratory confirmed with RT-PCR, suspected with symptoms and contacts, or radiologically suspected cases with lung imaging features consistent with COVID-19 pneumonia and symptoms. Patients of any age, sex, histology, or stage were considered eligible, including those in active treatment and clinical follow-up. Clinical data will be extracted from medical records of consecutive patients from Jan 1, 2020 and will be collected until the end of the pandemic declared by WHO. Data on demographics, oncological history and comorbidities, COVID-19 diagnosis, and course of illness and clinical outcomes will be collected. Associations between demographic or clinical characteristics and outcomes will be measured with odds ratios (ORs) with 95% CIs using univariable and multivariable logistic regression, with established prognostic factors included in multivariable analysis. The registry continues to accept new sites and patient data.
Clinical trial identification
NCT04632173.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.